DigitalDx Ventures

Biotia, Inc. is a health technology company based in New York, founded in 2016. The company specializes in developing software that utilizes DNA sequencing and artificial intelligence to identify and mitigate pathogens and antimicrobial threats before they can cause illness. By leveraging next-generation sequencing and advanced software solutions, Biotia enables clinicians and researchers to enhance patient treatment and improve health outcomes through rapid precision in infectious disease discovery.

GLX Analytix is a biotech company focused on enhancing healthcare through the development of a proprietary class of blood biomarkers combined with artificial intelligence. The company's innovative approach aims to facilitate early diagnosis and ongoing monitoring of chronic diseases, empowering patients to take an active role in their health management. By providing tools that monitor disease progression and predict potential flare-ups, GLX Analytix helps clinicians optimize treatment plans and improve patient outcomes. Recognized as an Industrial Partner to Harvard Medical/Wyss Diagnostic Accelerator and awarded the Roche Future of Healthcare Award, GLX Analytix is committed to improving lives globally by advancing personalized medicine and enabling more effective healthcare solutions.

Optina Diagnostics Inc. is a Canadian company based in Montréal, established in 2010, that focuses on the early detection of Alzheimer’s disease through advanced ocular imaging technology. The company has developed a retinal imaging test that utilizes hyperspectral imaging to identify key biomarkers associated with Alzheimer’s, including beta-amyloid plaques. In addition to Alzheimer’s detection, its imaging systems also aid in diagnosing age-related macular degeneration and ocular diabetic retinopathy. By providing a simple eye exam, Optina's technology enables healthcare professionals to detect and address the underlying causes of memory loss, thereby contributing to improved patient care and outcomes in neurodegenerative diseases.

Developer of a urine-based diagnostic tool designed to predict and prevent the progression of kidney disease. The company's tool permits quantitative measurement of biomarkers for the early detection and lifetime monitoring of kidney disease, enabling physicians to detect acute rejection of kidney transplants noninvasively.

AEENA Dx focuses on enhancing breast cancer detection through innovative biofluid-based molecular diagnostic tests. The company aims to improve the accuracy, efficiency, accessibility, and affordability of breast cancer screening for women. By providing genetic biomarkers-on-demand, AEENA Dx operates through fee-for-service arrangements and collaboration agreements. The organization also utilizes data from commercially available microarrays to generate results. Founded in 2011 and based in San Francisco, California, AEENA Dx comprises a team of experts in molecular diagnostics, genomics, and data science, committed to driving significant advancements in healthcare.

Optina Diagnostics Inc. is a Canadian company based in Montréal, established in 2010, that focuses on the early detection of Alzheimer’s disease through advanced ocular imaging technology. The company has developed a retinal imaging test that utilizes hyperspectral imaging to identify key biomarkers associated with Alzheimer’s, including beta-amyloid plaques. In addition to Alzheimer’s detection, its imaging systems also aid in diagnosing age-related macular degeneration and ocular diabetic retinopathy. By providing a simple eye exam, Optina's technology enables healthcare professionals to detect and address the underlying causes of memory loss, thereby contributing to improved patient care and outcomes in neurodegenerative diseases.